Serious adverse events (total n = 78)
| . | Month of serious adverse event . | Serious adverse event . |
|---|---|---|
| During treatment (before mo 16; n = 64) | Reported in supplemental Table 1 | |
| During follow-up (from mo 16; n = 14) | 17 | Hyperthermia |
| 17 | Pneumocystis | |
| 18 | Neutropenia (grade 4) | |
| 18 | Neutropenia (grade 3) | |
| 18 | Squamous cell carcinoma of skin | |
| 20 | Aspergillosis pulmonary | |
| 20 | Macrophage activation | |
| 37 | Melanocytic intraepithelial neoplasia (low grade) | |
| 37 | Invasive differentiated squamous cell carcinoma of oral cavity | |
| 39 | Multiple malignant metastases | |
| 50 | Metastatic prostate adenocarcinoma | |
| 60 | Myelodysplastic syndrome | |
| 65 | Cerebrovascular accident | |
| 69 | Acute myeloid leukemia | |
| . | Month of serious adverse event . | Serious adverse event . |
|---|---|---|
| During treatment (before mo 16; n = 64) | Reported in supplemental Table 1 | |
| During follow-up (from mo 16; n = 14) | 17 | Hyperthermia |
| 17 | Pneumocystis | |
| 18 | Neutropenia (grade 4) | |
| 18 | Neutropenia (grade 3) | |
| 18 | Squamous cell carcinoma of skin | |
| 20 | Aspergillosis pulmonary | |
| 20 | Macrophage activation | |
| 37 | Melanocytic intraepithelial neoplasia (low grade) | |
| 37 | Invasive differentiated squamous cell carcinoma of oral cavity | |
| 39 | Multiple malignant metastases | |
| 50 | Metastatic prostate adenocarcinoma | |
| 60 | Myelodysplastic syndrome | |
| 65 | Cerebrovascular accident | |
| 69 | Acute myeloid leukemia | |